Sage Journals: Discover world-class research

Abstract

Purpose:

This study aims to generate a more potent oncolytic adenovirus, Ad.hTERT-E1A/CMV-CD, which combines therapeutic gene and oncolytic effect.

Methods:

A human telomerase reverse transcriptase (hTERT) gene promoter was used to regulate the expression of adenoviral immediate-early gene 1A (E1A) to induce selective replication of recombinant adenovirus in tumor cells. To further enhance antitumor effect, a cytomegalovirus (CMV) promoter-driven Escherichia coli cytosine deaminase (CD) gene expression cassette was further incorporated into E1 region and the antitumor effect of this novel adenovirus was evaluated in vitro and in vivo.

Results:

Ad.hTERT-E1A/CMV-CD was capable to selectively replicate and lyse in various human tumor cell lines, including NCIH460, SW1990, and HeLa, while causing no damage to primary fibroblasts. The combined therapy of Ad.hTERT-E1A/CMV-CD with prodrug 5-fluorocytosine (5-FC) elicited a greater killing effect on tumor cells than Ad.hTERT-E1A/CMV-CD alone, and it synergistically suppressed tumor growth in BALB/c nude mice bearing human lung tumor.

Conclusions:

As telomerase is reactivated in a broad spectrum of tumors and prodrug 5-FC is much safe than its metabolized 5-fluorouracil, a chemotherapeutic agent in the treatment of many malignancies, Ad.hTERT-E1A/CMV-CD in combination with 5-FC may be a potential strategy for the treatment of a wide range of solid tumors.

Get full access to this article

View all access options for this article.

References

Amato

, Drury

, Naylor

et al. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): A phase 2 trial. J Immunother, 2008; 31:577.

Forsyth

, Roldán

, George

et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther, 2008; 16:627.

Kemeny

, Brown

, Covey

et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther, 2006; 17:1214.

Laurie

, Bell

, Atkins

et al. Phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res, 2006; 12:2555.

Liu

, Kirn

. Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions. Cancer Res, 2007; 67:429.

Myers

, Harvey

, Kaufmann

et al. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. Hum Gene Ther, 2008; 19:690.

Haviv

, Curiel

. Engineering regulatory elements for conditionally-replicative adeno-viruses. Curr Gene Ther, 2003; 3:357.

Uchino

, Takayama

, Harada

et al. Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment. Cancer Gene Ther, 2005; 12:737.

Chiocca

, Abbed

, Tatter

. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther, 2004; 10:958.

10.

Nemunaitis

, Senzer

, Sarmiento

. A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients. Cancer Gene Ther, 2007; 14:885.

11.

Dix

, Edwards

, Braithwaite

. Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? J Virol, 2001; 75:5443.

12.

Geoerger

, Grill

, Opolon

et al. Oncolytic Activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res, 2002; 62:764.

13.

, Andreeff

, Roth

et al. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther, 2002; 9:30.

14.

Meyerson

. Role of telomerase in normal and cancer cells. J Clin Oncol, 2000; 18:2626.

15.

Huang

, Zhang

, Wang

et al. A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin Cancer Res, 2004; 10:1439.

16.

Irving

, Wang

, Powell

et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther, 2004; 11:174.

17.

Kim

, Kim

, Shin

et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther, 2003; 14:1415.

18.

Lanson

Jr , Friedlander

, Schwarzenberger

et al. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res, 2003; 63:7936.

19.

Wirth

, Zender

, Schulte

et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res, 2003; 63:3181.

20.

Miller

, Williams

, Buchsbaum

et al. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res, 2002; 62:773.

21.

Bentires-Alj

, Hellin

, Lechanteur

et al. Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther, 2000; 7:20.

22.

Freytag

, Khil

, Stricker

et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res, 2002; 62:4968.

23.

Zhang

, Nie

, Sham

et al. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene. Cancer Res, 2004; 64:5390.

24.

Lohr

, Huang

, Hu

et al. Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors. Clin Cancer Res, 2001; 7:3625.

25.

Wildner

, Hoffmann

, Jogler

et al. Comparison of HSV-1 thymidine kinase-dependent and independent inhibition of replication-competent adenoviral vectors by a panel of drugs. Cancer Gene Ther, 2003; 10:791.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.78 MB

A Novel Oncolytic Adenovirus Expressing Escherichia coli Cytosine Deaminase Exhibits Potent Antitumor Effect on Human Solid Tumors